Adalimumab therapy for recalcitrant pyoderma gangrenosum.
Article Details
- CitationCopy to clipboard
Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH
Adalimumab therapy for recalcitrant pyoderma gangrenosum.
J Burns Wounds. 2006 Nov 20;5:e8.
- PubMed ID
- 17149453 [ View in PubMed]
- Abstract
OBJECTIVE: To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach. METHODS: Case report and review of the literature. RESULTS: A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated. CONCLUSIONS: We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.
DrugBank Data that Cites this Article
- Drugs